Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Liabilities: 2015-2024

Historic Other Non-Current Liabilities for Intellia Therapeutics (NTLA) over the last 4 years, with Dec 2024 value amounting to $130.0 million.

  • Intellia Therapeutics' Other Non-Current Liabilities was N/A to $130.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $130.0 million, marking a year-over-year change of. This contributed to the annual value of $130.0 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Intellia Therapeutics reported Other Non-Current Liabilities of $130.0 million as of Q4 2024, which was up 441.08% from $24.0 million recorded in Q4 2022.
  • In the past 5 years, Intellia Therapeutics' Other Non-Current Liabilities ranged from a high of $130.0 million in Q4 2024 and a low of $10.8 million during Q2 2022.
  • Moreover, its 2-year median value for Other Non-Current Liabilities was $18.6 million (2022), whereas its average is $38.9 million.